Novel proteasome inhibitors as potential drugs to combat tuberculosis

Journal of Molecular Cell Biology
Yong Cheng, Jean Pieters

Abstract

Mycobacterium tuberculosis is one of the most notorious killers worldwide. These pathogens have evolved to infect human beings in a so-called dormant form that is extremely difficult to treat. New work, however, suggests that mycobacterial proteasomes, multicomponent structures that protect the microbe from damaging effects of nitric oxide generated by the host, can be selectively and specifically blocked by small molecules.

References

Aug 30, 2000·Nature·D Butler
Mar 1, 2002·Advances in Protein Chemistry·P ZwicklW Baumeister
Oct 7, 2003·Annual Review of Microbiology·Christine L CosmaLalita Ramakrishnan
Mar 8, 2007·Nature Medicine·Digby F Warner, Valerie Mizrahi
Jun 11, 2008·Cell Host & Microbe·Jean Pieters
Mar 12, 2009·Current Medicinal Chemistry·Li Huang, Chin Ho Chen
Mar 14, 2009·Annual Review of Pharmacology and Toxicology·Liem Nguyen, Jean Pieters

❮ Previous
Next ❯

Citations

Jul 16, 2013·European Journal of Medicinal Chemistry·Pieter ClaesNorbert De Kimpe
Oct 22, 2011·PloS One·Sanja AveicGiuseppe Basso
Oct 16, 2014·BMC Complementary and Alternative Medicine·Yuejuan ZhengHuiyong Zhang
Apr 10, 2013·European Journal of Medicinal Chemistry·Davie CappoenKris Huygen
Oct 31, 2012·Expert Review of Anti-infective Therapy·Rajesh JayachandranJean Pieters
Oct 26, 2013·European Surgical Research. Europäische Chirurgische Forschung. Recherches Chirurgicales Européennes·O M DisliH Parlakpinar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.